Drug Discovery

FDA accepts for priority review Seagen’s sNDA for colorectal cancer medicine

The US Food and Drug Administration (FDA) has accepted for priority review Seagen’s supplemental New Drug Application (sNDA) seeking accelerated approval for its medicine tukysa (tucatinib) along with trastuzumab to treat colorectal cancer.

NeuroBo signs license deal with Dong-A ST to develop two drug candidates

NeuroBo Pharmaceuticals has signed a conditional exclusive license agreement with Dong-A ST for the development and commercialisation of the latter’s cardio-metabolic therapies, DA-1241 and DA-1726.

Coave, IMN partner to develop gene therapy for neurodegenerative disorders

Coave Therapeutics and the Institute of Neurodegenerative Diseases (IMN) of Bordeaux have entered into collaboration for developing gene therapy programmes that target protein degradation in neurodegenerative disorders.

Novome raises funds to advance microbes’ pipeline

Novome Biotechnologies has raised $43.5m in a Series B financing round to advance its therapeutically engineered microbes’ pipeline.

Pfizer’s GBS6 receives FDA Breakthrough Therapy Designation

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s GBS6 or PF-06760805 to prevent invasive Group B Streptococcus (GBS) disease in new-borns and infants through immunisation of women during pregnancy.

Bristol Myers Squibb acquires Turning Point for $4.1bn

Bristol Myers Squibb has completed the previously announced acquisition of Turning Point Therapeutics, for a total consideration of $4.1bn in cash.

Senda raises funds to advance programmable medicines platform development

Senda Biosciences has raised $123m in Series C financing round to advance the development of its programmable medicines’ platform into clinical testing.

Epigenic Therapeutics secures funds to advance gene editing therapy

Chinese biotechnology firm Epigenic Therapeutics has secured $20m in Series Angel and Pre-A funding to proceed with next-generation gene editing therapy.

TransCode and MD Anderson partner to advance RNA-targeted cancer therapies

TransCode Therapeutics has entered into a strategic alliance with the University of Texas MD Anderson Cancer Center for advancing its RNA therapies for oncology.